🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "significant breakthrough" in the battle against increasingly resistant strains of the bacteria, according to health experts.

An International Public Health Issue

The sexually transmitted infection are increasing worldwide, with estimates suggesting more than 82 million infections annually. Notably increased rates are reported in the African continent and nations within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have reached a record high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune development in the context of rising global incidence, increasing antimicrobial resistance and the very limited treatment choices presently on offer.”

Medical experts are increasingly worried about the increase in treatment-resistant strains. The World Health Organization has listed it as a "critical concern". Ongoing monitoring showed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Receive Clearance

One new antibiotic, also known as a brand name, was cleared by the American regulatory agency in recent days for treating gonorrhoea. This infection can lead to serious health problems, including infertility. Experts anticipate that focused deployment of this new drug will help slow the development of resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This treatment, which is additionally indicated for UTIs, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin was the result of a innovative non-profit model for drug creation. The charitable organization GARDP collaborated with the pharmaceutical company Innoviva to see it through.

“This milestone represents a significant shift in the treatment of multidrug-resistant gonorrhoea, which previously has been outpacing medical innovation.”

Clinical Trial Data and Global Access

As per data published in a major medical journal, the new drug cured the vast majority of cases of the STI. This establishes an comparable level with the current standard treatment, which combines two antibiotics. The research involved hundreds of patients from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the ability to register and commercialise the drug in a wide range of developing nations.

Medical professionals directly involved have expressed optimism. Access to a one-pill regimen like this is described as a "revolutionary step" for managing the epidemic. This is considered essential to alleviate the strain of the infection for patients and to halt the transmission of untreatable gonorrhoea around the world.